Description: VIR-7831 (GSK4182136) is an anti-SARS-CoV-2 antibody that could be used to treat mild-to-moderate COVID-19 infections. The antibody can achieve high concentrations in the lungs.
Development status: The two companies have launched a Phase 3 clinical trial to study the safety and efficacy of VIR-7831 to treat hospitalized adults with COVID-19. The study, known as ACTIV-3, is part of a series of trials from the NIH.
In October, GSK stated that interim Phase 3 results could be available before the end of the year and that it expected results from the primary endpoint of the trial in the first quarter of 2021.
Filed Under: clinical trials, Drug Discovery, Infectious Disease